Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Sonia Guedan: ARI-HER2 CAR-T Trial Moves Closer to Treating Patients With HER2-Positive mBC

ARI-HER2 CAR-T Trial Wins AEMPS Approval for HER2+ Breast Cáncer

November 21, 2026 Health Desk Health

The ARI-HER2 clinical trial has received regulatory approval from the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) to begin testing in patients with HER2-positive metastatic breast cancer.

Key Clinical Takeaways:

  • The trial utilizes a CAR-T cell therapy designed to target tumor cells with high HER2 expression while sparing healthy tissue.
  • The therapy incorporates a 4-1BB costimulatory domain to enhance its biological activity against solid tumors.
  • Site initiation is complete, marking the transition from laboratory research to the first human clinical applications.

The AEMPS authorization follows years of collaborative development at the Hospital Clínic de Barcelona and the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Sonia Guedan, Principal Investigator and Ramon y Cajal Fellow at IDIBAPS, confirmed that the site initiation visit is complete, Oncodaily reported.

“From the lab to the clinic: ARI-HER2 takes an important step forward! The ARI-HER2 clinical trial has received regulatory approval by Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), and the site initiation visit has been successfully completed, bringing us one step closer to treating the first patients with HER2-positive metastatic breast cancer.”

This statement was shared by Guedan on LinkedIn. The project has involved extensive institutional support from SOLTI, Hospital 12 de Octubre, and the Clínica Universidad de Navarra, with additional backing from the Asociación Española contra el Cáncer (AECC).

The ARI-HER2 therapy is engineered to overcome the difficulties of treating solid tumors with CAR-T cells. According to the project specifications, the therapy uses a low-affinity receptor to recognize the HER2 protein.

This design choice aims to create a threshold for activation, ensuring that only cells expressing high levels of HER2 are targeted. By minimizing the recognition of healthy tissues, which express lower levels of the protein, the researchers intend to improve the safety profile of the treatment.

The construct is built around a 4-1BB costimulatory domain, a component commonly utilized in CAR-T designs to improve the persistence and survival of the modified T cells within the tumor microenvironment. This approach aims to increase the effectiveness of adoptive cell therapies for solid malignancies, where tumor heterogeneity and antigen density often limit results.

The research team has indicated that further documentation regarding the science behind the ARI-HER2 platform is forthcoming. While the current focus remains on the initiation of the trial, the researchers anticipate sharing detailed manuscripts soon. For patients and clinicians monitoring advancements in breast cancer therapy, it is essential to remain informed through discussions with medical oncologists who specialize in experimental therapeutics and clinical research protocols.

As the field moves toward more precise cellular immunotherapies, the integration of these trials into established hospital networks remains a priority. Patients interested in the eligibility criteria for emerging CAR-T studies should consult with clinical trial coordinators or specialized oncology centers that maintain active portfolios of immunotherapy research.

Operating as an autonomous agency of the Government of Spain, the Agencia Española de Medicamentos y Productos Sanitarios acts as the country’s highest sanitary authority regarding medical safety. Originally created under the name of Agencia Española del Medicamento, the organization acquired its current name in August 2003 and functions directly under the Ministry of Health to oversee medicines, health products, cosmetics, and personal care products.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Worth a look

  • Psychiatrists and Psychologist Share Tips to Manage Holiday Mental Load
  • Key Clinical Takeaways
  • SpaceX Share for Every Kid Needs a Charity and Treasury's Approval (daybreakwire.com)
  • Jessie J Returns to Instagram After Breast Reconstruction Surgery (newsdirectory3.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service